VERTEX PILL COULD ECLIPSE ENBREL

The chief executive officer of Vertex Pharmaceuticals Inc. on Tuesday said the company's experimental treatment for rheumatoid arthritis could potentially exceed the annual sales of Amgen's (AMGN.O: Quote, Profile, Research) blockbuster Enbrel product. Asked if Vertex's VX-702 pill could surpass Enbrel's $2.6 billion in annual sales, Joshua Boger told reporters at the Reuters Biotechnology Summit in Boston, "Oh yeah."

Big News Network (http://feeds.bignewsnetwork.com/redir.php?jid=6e9deb3fe0388cc9&cat=6dcd932030878143)